Clinical Trials Browser

Recruiting × Neoplasms × Decitabine × Clear all

NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Phase 1/2 Recruiting

Neoplasms, Recurrence